Compare · DXCM vs INFU
DXCM vs INFU
Side-by-side comparison of DexCom Inc. (DXCM) and InfuSystems Holdings Inc. (INFU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and INFU operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $40.07B, about 127.3x INFU ($314.7M).
- Over the past year, DXCM is down 13.5% and INFU is up 107.9% - INFU leads by 121.4 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 1 for INFU).
- DXCM has more recent analyst coverage (25 ratings vs 3 for INFU).
- Company
- DexCom Inc.
- InfuSystems Holdings Inc.
- Price
- $61.55-1.84%
- $10.31+0.49%
- Market cap
- $40.07B
- $314.7M
- 1M return
- -7.89%
- +5.31%
- 1Y return
- -13.51%
- +107.86%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 3
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
InfuSystems Holdings Inc.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest INFU
- SEC Form DEF 14A filed by InfuSystems Holdings Inc.
- InfuSystems Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InfuSystem to Participate at 38th Annual ROTH Conference on March 23, 2026
- Executive VP and CFO Steele Barry G bought $18,906 worth of shares (2,064 units at $9.16), increasing direct ownership by 2% to 88,000 units (SEC Form 4)
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by InfuSystems Holdings Inc.
- InfuSystems Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2025
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits